EB House Austria

Recent papers from EB House Austria

1. Immunofluorescence mapping vs. electron microscopy in epidermolysis bullosa: comparative retrospective study in 84 genetically confirmed patientsOrphanet Journal of Rare Diseases · 2026
2. Clinical trial awareness and participation attitudes among patients with epidermolysis bullosa and their caregivers: a nationwide cross-sectional study from Saudi ArabiaFrontiers in Medicine · 2026
3. RiboScreenTM Technology Delivers Small-Molecule Ribodrugs to Convert Ribosomal Proteins into Molecular Valves for Tailored Protein Production Levels in Rare and Prevalent DiseaseBiomedicines · 2026
4. Harnessing skin-resident γδ T cells for immunotherapy in cutaneous squamous cell carcinomaScience Advances · 2026
5. Engineered natural extracellular matrix platform for modelling skin diseases and therapeutic targets discoveryJournal of Advanced Research · 2026
6. Long-term cytokine exposure remodels the methylome and transcriptome of recessive dystrophic epidermolysis bullosa keratinocytes – a bioinformatic analysisFrontiers in Cell and Developmental Biology · 2026
7. Herpes virus-based therapeutics in dermato-oncology – Past, present and future perspectivesZooKeys · 2026
8. Meta-Analysis of Pain Management in Epidermolysis BullosaBritish Journal of Dermatology · 2026
9. Lipid nanoparticle-based non-viral in situ gene editing of congenital ichthyosis-causing mutations in human skin modelsCell stem cell · 2026
10. Transcriptome-guided drug repurposing identifies selumetinib for an aggressive epithelial cancerJournal of Investigative Dermatology · 2025
11. Patient-reported outcomes during pregnancy and delivery in epidermolysis bullosaBMC Pregnancy and Childbirth · 2025
12. Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosaMolecular Therapy · 2025
13. Core outcome domain sets for clinical trials in epidermolysis bullosa — a COSEB protocol to achieve consensus on “what” to measureTrials · 2025
14. Epigenetic Age Monitoring in Professional Soccer Players for Tracking Recovery and the Effects of Strenuous ExerciseAging Cell · 2025
15. Keratin-associated epidermolysis bullosa simplex: phenotypes and challenges in clinical trials – a narrative review and systematic updateOrphanet Journal of Rare Diseases · 2025
16. Efficacy and safety of rigosertib in patients with recessive dystrophic epidermolysis bullosa-associated advanced/metastatic cutaneous squamous cell carcinomaBritish Journal of Dermatology · 2025
17. A Novel Homozygous 9385 bp Deletion in the FERMT1 (KIND1) Gene in a Malaysian Family with Kindler Epidermolysis bullosa and a Review of Large DeletionsInternational Journal of Molecular Sciences · 2025
18. Repurposing diacerein for the treatment of chronic wounds in recessive‐dystrophic epidermolysis bullosa patients by modulating matrix metalloproteinase‐9 expressionThe Journal of Dermatology · 2025
19. Learning From Listening To A Citizen BoardMuseological Review · 2025
20. Philanthropic drug development: understanding its importance, mechanisms, and future prospectsDrug Discovery Today · 2025